Novo Nordisk A/S (B Shares) ADRhedged

Viking Therapeutics (VKTX) is a biotech company developing a weight loss drug candidate that has shown promising results in clinical trials. The company aims to launch a phase 3 trial for the injectable version of VK2735 in the second quarter. Despite recent stock declines, the article suggests that Viking could be a good buy considering the high-growth weight loss drug market opportunity and the company's progress.

Related tickers: VKTX, LLY, NVOH.

Eli Lilly announced plans to acquire Organovo's FXR program and launched larger-dose vials of its weight loss drug Zepbound at lower prices, causing its stock to rise 2.6% despite a market downturn.

Related tickers: LLY, ONVO, NVOH, HIMS.